These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
☒
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
☐
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
Delaware
(
State or Other Jurisdiction of Incorporation or Organization)
|
11-3027591
(IRS Employer Identification No.) |
|
445 Park Avenue, Suite 912
New York, New York
(Address of Principal Executive Offices)
|
10022
(Zip Code)
|
|
Page No.
|
|
|
PART I. Financial Information
|
|
|
Item 1. Condensed Consolidated Financial Statements (unaudited)
|
|
|
Condensed Consolidated Balance Sheets as of September 30, 2016 and December 31, 2015
|
3 |
|
Condensed Consolidated Statements of Operations and Comprehensive Income for the three and nine months ended September 30, 2016 and 2015
|
4 |
|
Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2016 and 2015
|
5 |
|
Notes to Unaudited Condensed Consolidated Financial Statements
|
6 |
|
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
|
26 |
|
Item 3. Quantitative and Qualitative Disclosures About Market Risk
|
35 |
|
Item 4. Controls and Procedures
|
35 |
|
PART II. Other Information
|
|
|
Item 1. Legal Proceedings
|
35 |
|
Item 1A. Risk Factors
|
38 |
|
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
|
38 |
|
Item 3. Defaults Upon Senior Securities
|
39 |
|
Item 5. Other Information
|
39 |
|
Item 6. Exhibits
|
40 |
|
Signatures
|
41 |
|
ASSETS:
|
September 30,
2016
|
December 31,
2015
|
||||||
|
CURRENT ASSETS:
|
||||||||
|
Cash and cash equivalents
|
$
|
57,759,000
|
$
|
20,608,000
|
||||
|
Marketable securities, available for sale
|
1,100,000
|
1,061,000
|
||||||
|
Royalty receivables
|
1,414,000
|
1,537,000
|
||||||
|
Other current assets
|
20,000
|
196,000
|
||||||
|
Total Current Assets
|
60,293,000
|
23,402,000
|
||||||
|
OTHER ASSETS:
|
||||||||
|
Deferred tax assets
|
415,000
|
4,958,000
|
||||||
|
Patents, net of accumulated amortization
|
1,246,000
|
2,002,000 | ||||||
|
Security deposits
|
19,000
|
19,000
|
||||||
|
Total Other Assets
|
1,680,000
|
6,979,000
|
||||||
|
TOTAL ASSETS
|
$
|
61,973,000
|
$
|
30,381,000
|
||||
|
LIABILITIES AND STOCKHOLDERS' EQUITY:
|
||||||||
|
CURRENT LIABILITIES:
|
||||||||
|
Accounts payable
|
$
|
462,000
|
$
|
139,000
|
||||
|
Accrued expenses
|
5,572,000
|
1,552,000
|
||||||
|
Income taxes payable
|
4,080,000
|
—
|
||||||
|
TOTAL LIABILITIES
|
10,114,000
|
1,691,000
|
||||||
|
COMMITMENTS AND CONTINGENCIES
|
||||||||
|
STOCKHOLDERS' EQUITY
|
||||||||
|
Preferred stock, $0.01 par value, authorized 10,000,000 shares;
|
||||||||
|
none issued and outstanding at September 30, 2016 and
|
||||||||
|
December 31, 2015
|
—
|
—
|
||||||
|
Common stock, $0.01 par value; authorized 50,000,000 shares;
|
||||||||
|
23,329,196 and 23,211,149 shares issued and outstanding at
|
||||||||
|
September 30, 2016 and December 31, 2015, respectively
|
233,000
|
232,000
|
||||||
|
Additional paid-in capital
|
61,540,000
|
61,249,000
|
||||||
|
Accumulated deficit
|
(9,918,000
|
)
|
(32,756,000
|
)
|
||||
|
Accumulated other comprehensive income(loss)
|
4,000
|
(35,000
|
)
|
|||||
|
TOTAL STOCKHOLDERS' EQUITY
|
51,859,000
|
28,690,000
|
||||||
|
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY
|
$
|
61,973,000
|
$
|
30,381,000
|
||||
|
Three Months Ended
September 30,
|
Nine Months Ended
September 30,
|
|||||||||||||||
|
2016
|
2015
|
2016
|
2015
|
|||||||||||||
|
REVENUE
|
$
|
34,326,000
|
$
|
3,008,000
|
$
|
59,963,000
|
$
|
10,382,000
|
||||||||
|
OPERATING EXPENSES:
|
||||||||||||||||
|
Costs of revenue
|
16,943,000
|
927,000
|
24,183,000
|
3,094,000
|
||||||||||||
|
Professional fees and related costs
|
633,000
|
475,000
|
1,458,000
|
1,248,000
|
||||||||||||
|
General and administrative
|
428,000
|
440,000
|
1,256,000
|
1,891,000
|
||||||||||||
|
Amortization of patents
|
49,000
|
413,000
|
760,000
|
1,239,000
|
||||||||||||
|
Stock-based compensation
|
189,000
|
69,000 |
233,000
|
243,000
|
||||||||||||
|
Contingent patent cost
|
—
|
—
|
500,000
|
—
|
||||||||||||
|
TOTAL OPERATING EXPENSES
|
18,242,000
|
2,324,000
|
28,390,000
|
7,715,000
|
||||||||||||
|
OPERATING INCOME
|
16,084,000
|
684,000
|
31,573,000
|
2,667,000
|
||||||||||||
|
OTHER INCOME:
|
||||||||||||||||
|
Interest income, net
|
24,000
|
11,000
|
50,000
|
44,000
|
||||||||||||
|
INCOME BEFORE INCOME TAXES
|
16,108,000
|
695,000
|
31,623,000
|
2,711,000
|
||||||||||||
|
INCOME TAXES:
|
||||||||||||||||
|
Current
|
3,817,000
|
26,000
|
4,198,000
|
66,000
|
||||||||||||
|
Deferred taxes, net
|
1,459,000
|
262,000
|
4,543,000
|
928,000
|
||||||||||||
|
Total income taxes
|
5,276,000
|
288,000
|
8,741,000
|
994,000
|
||||||||||||
|
NET INCOME
|
$
|
10,832,000
|
$
|
407,000
|
$
|
22,882,000
|
$
|
1,717,000
|
||||||||
|
Net Income Per Share
|
||||||||||||||||
|
Basic
|
$
|
0.46
|
$
|
0.02
|
$
|
0.98
|
$
|
0.07
|
||||||||
|
Diluted
|
$
|
0.43
|
$
|
0.02
|
$
|
0.93
|
$
|
0.07
|
||||||||
|
Weighted average common shares outstanding:
|
||||||||||||||||
|
Basic
|
23,320,514
|
23,273,946
|
23,291,408
|
23,597,143
|
||||||||||||
|
Diluted
|
25,198,142
|
24,654,699
|
24,700,784
|
24,590,487
|
||||||||||||
|
NET INCOME
|
$
|
10,832,000
|
$
|
407,000
|
$
|
22,882,000
|
$
|
1,717,000
|
||||||||
|
OTHER COMPREHENSIVE INCOME:
|
||||||||||||||||
|
Unrealized holding gain (loss) on securities available-for-sale arising during the period
|
(4,000
|
)
|
12,000
|
39,000
|
—
|
|||||||||||
|
COMPREHENSIVE INCOME
|
$
|
10,828,000
|
$
|
419,000
|
$
|
22,921,000
|
$
|
1,717,000
|
||||||||
|
Nine Months Ended
September 30,
|
||||||||
| 2016 | 2015 | |||||||
|
CASH FLOWS
FROM OPERATING ACTIVITIES:
|
||||||||
|
Net Income
|
$
|
22,882,000
|
$
|
1,717,000
|
||||
|
Adjustments to reconcile net income to net cash
|
||||||||
|
provided by operating activities:
|
||||||||
|
Amortization of patents
|
760,000
|
1,239,000
|
||||||
|
Stock-based compensation
|
233,000
|
243,000
|
||||||
|
Deferred tax provision
|
4,543,000
|
928,000
|
||||||
|
Impairment of investments
|
—
|
386,000
|
||||||
|
Changes in operating assets and liabilities:
|
||||||||
|
Royalty receivables
|
123,000
|
(451,000
|
)
|
|||||
|
Other current assets
|
176,000
|
126,000
|
||||||
|
Accounts payable
|
323,000
|
(165,000
|
)
|
|||||
|
Accrued expenses
|
4,020,000
|
(1,082,000
|
)
|
|||||
|
Income taxes payable
|
4,080,000
|
—
|
||||||
|
NET CASH PROVIDED BY OPERATING ACTIVITIES
|
37,140,000
|
2,941,000
|
||||||
|
CASH FLOWS FROM INVESTING ACTIVITIES:
|
||||||||
|
Purchases of patents and other assets
|
(4,000
|
)
|
(36,000
|
)
|
||||
|
CASH FLOWS FROM FINANCING ACTIVITIES:
|
||||||||
|
Value of shares delivered to fund withholding taxes on exercise of options
|
(44,000
|
)
|
—
|
|||||
|
Repurchases of common stock, net of commissions
|
(1,000
|
)
|
(2,555,000
|
)
|
||||
|
Proceeds from exercise of options
|
60,000
|
—
|
||||||
|
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES
|
15,000
|
(2,555,000
|
)
|
|||||
|
NET INCREASE IN CASH AND CASH EQUIVALENTS
|
37,151,000
|
350,000
|
||||||
|
CASH AND CASH EQUIVALENTS, beginning of period
|
20,608,000
|
17,662,000
|
||||||
|
CASH AND CASH EQUIVALENTS, end of period
|
$
|
57,759,000
|
$
|
18,012,000
|
||||
|
|
||||||||
|
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
|
||||||||
|
CASH PAID DURING THE PERIOD FOR:
|
||||||||
|
Interest
|
$
|
—
|
$
|
—
|
||||
|
Taxes
|
—
|
50,000
|
||||||
|
September 30,
2016
|
December 31,
2015
|
|||||||
|
Gross carrying amount – patents
|
$
|
6,389,000
|
$
|
6,385,000
|
||||
|
Accumulated amortization – patents
|
(5,143,000
|
)
|
(4,383,000
|
)
|
||||
|
Patents, net
|
$
|
1,246,000
|
$
|
2,002,000
|
||||
| Twelve Months Ended September 30, | ||||
|
2017
|
$
|
196,000
|
||
|
2018
|
$
|
196,000
|
||
|
2019
|
$
|
193,000
|
||
|
2020
|
$
|
189,000
|
||
|
2021 and thereafter
|
$
|
472,000
|
||
|
Total
|
$
|
1,246,000
|
||
|
Number of Shares
|
Weighted-Average
Grant Date Fair Value
|
|||||||
|
Balance of restricted stock units outstanding at December 31, 2015
|
—
|
—
|
||||||
|
Issuance of restricted stock units
|
935,000
|
$
|
2.30
|
|||||
|
Vested restricted stock units
|
(33,750
|
)
|
$
|
(2.47
|
)
|
|||
|
Balance of unvested restricted stock units at September 30, 2016
|
901,250
|
$
|
2.14
|
|||||
|
Nine Months
Ended September 30, 2015 |
||
|
Risk-free interest rates
Expected option life in years
Expected stock price volatility
Expected dividend yield
|
1.39%
5 years
30.24%
-0-
|
|
Weighted
|
||||||||||
|
Weighted
|
Average
|
Weighted
|
||||||||
|
Range of
|
Average
|
Remaining
|
Average
|
|||||||
|
Exercise
|
Options
|
Exercise
|
Life in
|
Options
|
Exercise
|
|||||
|
Price
|
Outstanding
|
Price
|
Years
|
Exercisable
|
Price
|
|||||
|
$0.83 - $2.34
|
2,410,000
|
$1.29
|
2.90
|
2,410,000
|
$1.29
|
|
Number of
|
Exercise
|
||||
|
Warrants
|
Price
|
Expiration Date
|
|||
|
250,000
|
$2.10
|
May 21, 2018
|
|||
|
250,000
|
$1.40
|
May 21, 2018
|
|||
|
125,000
|
$2.10
|
July 26, 2018
|
|||
|
125,000
|
$1.40
|
July 26, 2018
|
|||
| Total |
750,000
|
|
|
Nine Months Ended
September 30, |
Three Months Ended
September 30,
|
||||||||||||||
| 2016 | 2015 | 2016 | 2015 | |||||||||||||
|
Current
|
||||||||||||||||
|
State
|
$
|
173,000
|
$
|
22,000
|
$
|
89,000
|
$
|
12,000
|
||||||||
|
Federal
|
4,025,000
|
44,000
|
3,728,000
|
14,000
|
||||||||||||
|
Total Current Tax Expense
|
4,198,000
|
66,000
|
3,817,000
|
26,000
|
||||||||||||
|
Deferred
|
||||||||||||||||
|
State
|
154,000
|
16,000
|
30,000
|
16,000
|
||||||||||||
|
Federal
|
4,389,000
|
912,000
|
1,429,000
|
246,000
|
||||||||||||
|
Total Deferred Tax Expense
|
4,543,000
|
928,000
|
1,459,000
|
262,000
|
||||||||||||
|
Total income taxes
|
$
|
8,741,000
|
$
|
994,000
|
$
|
5,276,000
|
$
|
288,000
|
||||||||
|
September 30,
|
December 31, | |||||||||
|
2016
|
2015
|
|||||||||
|
Deferred tax assets:
|
||||||||||
|
Net operating carryforwards
|
—
|
$
|
6,819,000
|
|||||||
|
Options, warrants and RSUs
|
415,000
|
419,000
|
||||||||
|
$
|
415,000
|
$
|
7,238,000
|
|||||||
|
Valuation allowance
|
—
|
(2,280,000
|
)
|
|||||||
|
Net deferred tax assets
|
$
|
415,000
|
$
|
4,958,000
|
||||||
|
Nine Months Ended
September 30,
|
Three Months Ended
September 30,
|
|||||||||||||||
|
2016
|
2015
|
2016
|
2015
|
|||||||||||||
|
Weighted-average common shares outstanding – basic
|
23,291,408
|
23,597,143
|
23,320,514
|
23,273,946
|
||||||||||||
|
Dilutive effect of options, warrants and restricted stock units
|
1,409,376
|
993,344
|
1,877,628
|
1,380,753
|
||||||||||||
|
Weighted-average common shares outstanding – diluted
|
24,700,784
|
24,590,487
|
25,198,142
|
24,654,699
|
||||||||||||
|
Options, warrants and restricted stock units excluded from the computation of diluted income (loss) per share because the effect of inclusion would have been anti-dilutive
|
141,304
|
105,000
|
423,913
|
105,000
|
||||||||||||
|
September 30, 2016
|
December 31, 2015
|
|||||||
|
Cash
|
$
|
17,583,000
|
$
|
6,283,000
|
||||
|
Money market fund
|
40,176,000
|
14,325,000
|
||||||
|
Total
|
$
|
57,759,000
|
$
|
20,608,000
|
||||
|
·
|
Revenue recognition;
|
|
·
|
Patents;
|
|
·
|
Income Taxes
|
|
·
|
Impairment of long lived assets; and
|
|
·
|
Stock based compensation.
|
|
·
|
Clarifying the Board's power to cancel, postpone or reschedule a meeting of stockholders;
|
|
·
|
Resolving an inconsistency regarding the eligibility requirements for stockholders to call special meetings and providing for procedural requirements in connection therewith;
|
|
·
|
Providing for an advance notice requirement for director nominations and stockholder proposals;
|
|
·
|
Clarifying the power of the Chairman of a stockholder meeting to regulate the conduct of the meeting;
|
|
·
|
Clarifying the power to fill director vacancies;
|
|
·
|
Modifying the requirements on removing directors from office;
|
|
·
|
Removing an obsolete provision with respect to the Company's ability to make loans to officers; and
|
|
·
|
Designating the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain legal action, unless the Company consents in writing to the selection of an alternative forum.
|
| 3.1 | Second Amended and Restated By-laws of the Company adopted on November 7, 2016. |
| 31.1 | Controls and Procedure Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.* |
| 31.2 | Controls and Procedure Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.* |
| 32.1 | Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.* |
| 32.2 | Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.* |
| 101 | Interactive data files:** |
| 101.INS | XBRL Instance Document |
| 101.SCH | XBRL Scheme Document |
| 101.CAL | XBRL Calculation Linkbase Document |
| 101.DEF | XBRL Definition Linkbase Document |
| 101.LAB | XBRL Label Linkbase Document |
| 101.PRE | XBRL Presentation Linkbase Document |
|
NETWORK-1 TECHNOLOGIES, INC.
|
|||
|
Date: November 10, 2016
|
By:
|
/s/ Corey M. Horowitz | |
|
Corey M. Horowitz
|
|||
|
Chairman and Chief Executive Officer
|
|||
|
Date: November 10, 2016
|
By:
|
/s/ David C. Kahn | |
|
David C. Kahn
|
|||
|
Chief Financial Officer
|
|||
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|